Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Common Equity (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Common Equity for 14 consecutive years, with -$292.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity fell 57.47% year-over-year to -$292.9 million, compared with a TTM value of -$292.9 million through Dec 2025, down 57.47%, and an annual FY2025 reading of -$292.9 million, down 57.47% over the prior year.
  • Common Equity was -$292.9 million for Q4 2025 at Karyopharm Therapeutics, down from -$269.3 million in the prior quarter.
  • Across five years, Common Equity topped out at -$16.7 million in Q4 2022 and bottomed at -$292.9 million in Q4 2025.
  • Average Common Equity over 5 years is -$134.6 million, with a median of -$129.1 million recorded in 2021.
  • The sharpest move saw Common Equity soared 79.09% in 2022, then plummeted 717.76% in 2023.
  • Year by year, Common Equity stood at -$79.7 million in 2021, then skyrocketed by 79.09% to -$16.7 million in 2022, then crashed by 717.76% to -$136.2 million in 2023, then plummeted by 36.57% to -$186.0 million in 2024, then plummeted by 57.47% to -$292.9 million in 2025.
  • Business Quant data shows Common Equity for KPTI at -$292.9 million in Q4 2025, -$269.3 million in Q3 2025, and -$238.9 million in Q2 2025.